Want to see JP:2385 full AI Analyst Report?
Top Page
Soiken Holdings Inc.
(2385)
Select Model
Select Model
Rating:55Neutral
Price Target:
¥229.00
▼(-2.97% Downside)
Action:Reiterated
Date:08/17/26
Overall score is driven mainly by mixed financial performance: a conservative, debt-free balance sheet supports resilience, but revenue contraction and historically inconsistent cash flows limit confidence in a sustained turnaround. Technicals are neutral with only modest momentum and weak longer-term trend confirmation, while valuation is balanced between an attractive dividend yield and a higher P/E.
Positive Factors
Debt-free balance sheet
Minimal leverage lowers refinancing risk and preserves financial flexibility through industry or operating downturns. The substantial equity base provides resilience while management addresses inconsistent profitability and supports ongoing business needs.
Negative Factors
Persistent revenue contraction
Repeated revenue declines can weaken operating leverage, reduce the scale of the business, and make fixed costs harder to absorb. Unless demand or product adoption improves, continued contraction could limit sustainable earnings and cash-flow growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Minimal leverage lowers refinancing risk and preserves financial flexibility through industry or operating downturns. The substantial equity base provides resilience while management addresses inconsistent profitability and supports ongoing business needs.
Read all positive factors
Soiken Holdings Inc. (2385) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.89B
Dividend Yield4.44%
Average Volume (3M)187.76K
Price to Earnings (P/E)27.7
Beta (1Y)0.75
Revenue Growth-20.15%
EPS GrowthN/A
CountryJP
Employees81
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.04
Shares Outstanding26,158,200
10 Day Avg. Volume461,280
30 Day Avg. Volume187,763
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)0.91
Price to Sales (P/S)1.44
P/FCF Ratio14.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Soiken Holdings Inc. Business Overview & Revenue Model
Company Description
Founded in 1994 and headquartered in Toyonaka, Japan, Soiken Holdings Inc. primarily focuses on the advancement of biomarkers. The company’s operations span a diverse range of health and wellness sectors. It is actively involved in the creation an...
Soiken Holdings Inc. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.85B | 3.87B | 4.85B | 5.16B | 8.08B | 9.35B |
| Gross Profit | 2.41B | 1.87B | 2.41B | 2.48B | 3.72B | 4.26B |
| EBITDA | -201.93M | 287.51M | -201.93M | -583.21M | 750.07M | 1.23B |
| Net Income | -210.41M | 212.29M | -210.70M | -662.20M | 451.85M | 809.71M |
Balance Sheet | ||||||
| Total Assets | 6.81B | 6.85B | 6.81B | 6.96B | 8.24B | 8.49B |
| Cash, Cash Equivalents and Short-Term Investments | 5.26B | 5.65B | 5.26B | 4.79B | 5.95B | 6.22B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 775.16M | 742.48M | 775.16M | 708.58M | 1.07B | 1.64B |
| Stockholders Equity | 6.02B | 6.11B | 6.02B | 6.23B | 6.97B | 6.65B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 377.20M | 521.19M | -895.42M | -141.08M | 2.09B |
| Operating Cash Flow | 0.00 | 415.15M | 557.96M | -880.82M | -101.55M | 2.14B |
| Investing Cash Flow | 0.00 | 119.10M | -389.41M | -14.29M | 160.37M | -244.58M |
| Financing Cash Flow | 0.00 | -139.80M | -214.00K | -260.71M | -130.21M | -129.94M |
Soiken Holdings Inc. Technical Analysis
Positive
236.00
Price Trends
218.77
Positive
228.97
Negative
230.61
Negative
Market Momentum
1.77
Negative
58.84
Neutral
69.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2385, the sentiment is Positive. The current price of 236 is above the 20-day moving average (MA) of 219.15, above the 50-day MA of 218.77, and above the 200-day MA of 230.61, indicating a neutral trend. The MACD of 1.77 indicates Negative momentum. The RSI at 58.84 is Neutral, neither overbought nor oversold. The STOCH value of 69.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2385.
Soiken Holdings Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | ¥5.89B | 27.71 | ― | 2.08% | -20.15% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥4.68B | -1.23 | ― | 5.44% | -21.55% | -497.97% | |
50 Neutral | ¥6.21B | -7.17 | ― | ― | 84.23% | 33.14% | |
49 Neutral | ¥4.23B | 133.47 | ― | ― | 2.37% | ― | |
45 Neutral | ¥7.07B | -6.16 | ― | ― | 12.73% | 25.71% | |
42 Neutral | ¥5.17B | -5.55 | ― | ― | ― | ― |
* Healthcare Sector Average
JP:2385
Soiken Holdings Inc.
225.00
41.80
22.81%
JP:2183
Linical Co., Ltd.
207.00
-118.93
-36.49%
JP:2342
Trans Genic Inc.
256.00
33.00
14.80%
JP:2370
MEDINET Co., Ltd.
25.00
-14.00
-35.90%
JP:4891
TMS Co., Ltd.
110.00
-46.00
-29.49%
JP:206A
PRISM BioLab Co. LTD
170.00
-10.00
-5.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.